Janusz Kłoczko Selected Research

ofatumumab

1/2020	A 5-year follow-up to evaluate the efficacy and safety of ofatumumab added to fludarabine and cyclophosphamide in patients with relapsed chronic lymphocytic leukemia: final analysis of the COMPLEMENT 2 trial.
1/2017	Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Janusz Kłoczko Research Topics

Disease

5	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2020 - 01/2014
4	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 08/2017 - 02/2008
3	Multiple Myeloma 03/2021 - 10/2002
3	Neoplasms (Cancer) 12/2015 - 10/2002
2	Leukemia 01/2014 - 02/2008
1	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2022
1	Monoclonal Gammopathy of Undetermined Significance 03/2021
1	Disease Progression 05/2018
1	monosomy Chromosome 7 10/2017
1	Down Syndrome (Down's Syndrome) 10/2017
1	Hemorrhage 01/2016
1	Neoplasm Metastasis (Metastasis) 01/2014
1	Residual Neoplasm 01/2008
1	Atrophy 11/2004
1	Renal Cell Carcinoma (Grawitz Tumor) 10/2002
1	Urinary Bladder Neoplasms (Bladder Cancer) 10/2002
1	Prostatic Hyperplasia (Benign Prostatic Hyperplasia) 10/2002
1	Cholecystolithiasis 08/2002
1	Venous Thrombosis (Deep-Vein Thrombosis) 03/2002

Drug/Important Bio-Agent (IBA)

3	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2020 - 01/2017
2	Tyrosine Kinase InhibitorsIBA 01/2022 - 10/2017
2	Bortezomib (Velcade)FDA Link 03/2021 - 12/2015
2	Proteasome InhibitorsIBA 03/2021 - 12/2015
2	ofatumumab FDA Link 01/2020 - 01/2017
2	Complement C2 (Complement Component 2)IBA 01/2020 - 01/2017
2	fludarabineIBA 01/2020 - 01/2017
2	Cladribine FDA LinkGeneric 05/2018 - 02/2008
2	Proteins (Proteins, Gene)FDA Link 01/2014 - 01/2008
1	ponatinibIBA 01/2022
1	Inosine Monophosphate (IMP)IBA 03/2021
1	carfilzomibIBA 03/2021
1	Rituximab (Mabthera)FDA Link 05/2018
1	Imatinib Mesylate (Gleevec)FDA Link 10/2017
1	Interferon-alpha (Interferon Alfa)IBA 10/2017
1	Carbapenems (Carbapenem Antibiotics)IBA 08/2017
1	Interleukin-2 Receptor alpha SubunitIBA 02/2016
1	AntibodiesIBA 01/2016
1	Death Domain ReceptorsIBA 01/2015
1	Indicators and Reagents (Reagents)IBA 01/2014
1	Interleukin-17 (Interleukin 17)IBA 01/2014
1	LigandsIBA 01/2014
1	AntigensIBA 01/2014
1	Heat-Shock Proteins (Heat-Shock Protein)IBA 01/2014
1	Mitoxantrone (Novantrone)FDA LinkGeneric 02/2008
1	Cytarabine (Cytosar-U)FDA LinkGeneric 02/2008
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 02/2008
1	Reticulin (Reticular Fiber)IBA 11/2004
1	CollagenIBA 11/2004
1	lipoprotein-associated coagulation inhibitor (TFPI)IBA 10/2002
1	Thromboplastin (Tissue Factor)IBA 10/2002
1	Thrombin FDA Link 08/2002
1	Protein CIBA 08/2002
1	Antithrombin IIIIBA 08/2002
1	plasmin-plasmin inhibitor complexIBA 03/2002
1	Fibrinolysin FDA Link 03/2002
1	antithrombin III-protease complexIBA 03/2002
1	fibrin fragment D (D-dimer)IBA 03/2002
1	Prothrombin (Factor II)IBA 03/2002

Therapy/Procedure

4	Therapeutics 01/2022 - 12/2015
1	Induction Chemotherapy 02/2016
1	Minor Surgical Procedures (Minor Surgery) 01/2016
1	Aftercare (After-Treatment) 01/2008
1	Laparoscopic Cholecystectomy 08/2002